 Six subjects aged 5-11 Cohort 1 were initially enrolled at the 8 mgkgday dose level. Upon completion of the study for these subjects, pharmacokinetic and safety data were analyzed to determine the target dose for the remaining subjects either 8, 10 or 12 mgkgday. Depending on the selected target dose, four additional age-based cohorts of subjects were to be enrolled. LCM was increased 2 mgkgday per week until the target dose or maximum dose able to be tolerated was achieved. 